One of the first small molecules aimed at disease pathogenesis was imatinib, a tyrosine kinase inhibitor for BCR-ABL-driven chronic myelogenous leukemia. Here, ABL1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.